The FDA is not required to accept, but traditionally follows the recommendations of its advisory panels. The panel recommended approval of the device contingent upon several conditions, including long-term follow up of current pivotal trial patients, a new post approval study of new patients and physicians, and more specific labeling recommendations.

«« Avista Capital to Acquire Bristol-Myers Squibb


Carestream Health Announces Launch of CAD Solution for CR Digital Mammography in Canada and Europe »»


Latest Articles

The FDA is not required to accept, but traditionally follows the recommendations of its advisory panels. The panel recommended approval of the device co...